Member Info for Professor1

Sorry ran out of space for the final point:

IMM could enter into a deal with a singular Rest-of-the-world BIG PHARMA CO for the Diagnostics + Therapeutics or we get acquired by one of the big UK pharma co. Avion in this case will have to deal with that big pharma co for the diagnostics and would Avion be able to afford the fees?

GLA

As I have already mentioned previously, what we have is:

(A) the original Agreement with Avion for jointly developing Lupus AND

(B) the new P140 Patent which includes, EXTREMELY IMPORTANTLY, the Diagnostic patent that was recently filed

THE ABOVE CREATES A DISTINCT TWO TIER STRUCTURE, IN MY VIEW, FOR THE US MARKET, BETWEEN THE ESTABLISHED DRUG RIGHTS AND THE NEW DIAGNOSTIC INTELLECTUAL PROPERTY (IP). I believe because of the complexities involved, we have not heard Tim mention a word about the US.

Taking the above (A) and (B) in a bit more detail, what we have is:

(A) US THERAPEUTIC RIGHTS (LUPUS + OTHER INDICATIONS)

(I) LUPUS - Under the 2019 Agreement, Avion has the right to exploit P140 for the development of LUPUS.

(ii) The Agreement has a "Future Indications" Clause under which Avion is allowed to "explore" other indications in the US 'UNDER THE EXISTING P140 THERAPEUTIC IP'.

PLEASE TAKE NOTE THAT THE AGREEMENT DOES NOT STATE FUTURE INDICATIONS UNDER ANY FUTURE IP

(B) THE NEW PATENT FILED IN SEPTEMBER 2025

This introduces a new diagnostic test to identify "Type M Responders". THIS WAS NOT PART OF THE ORIGINAL 2019 AGREEMENT.

1) I believe that because the Diagnostics is a NEW IP distinct from the original therapeutic patent, Avion DOES NOT automatically have the rights to this test and does not automatically own the rights AND

2) IMM, I believe, can treat the Diagnostics as a separate asset /IP

SO, WHAT DOES IT MEAN FOR IMM?

This means that Avion either :

(a) need to negotiate a NEW LICENSING DEAL WITH IMM

OR

(b) pay additional fees (dictated by IMM) for the use of the "TYPE M" test to select the patients for the US clinical trials.

The choice for Avion is clear - PAY UP OR continue funding the $25 million trials for LUPUS UNDER THE OLD P140 (and by the way keep paying us under the old Agreement) and not achieve the desired result WHILST WE WAVE THE FLAG TO THEM OF THE NEW P140.

I THINK THAT THE OLD DEAL WAS A THROW AWAY TO AVION AS FAR AS THE IMM SHAREHOLDERS WERE CONCERNED. THE NEW PATENT, AS TIM CALLS IT, IS TUELY A GAME CHANGER as it significantly enhances COMMERCIAL VALUE OF P140 across the 50 autoimmune diseases, not just Lupus.

SINCE THE DIAGNOSTIC CAPABILITY AND TYPE'M' INDICATION ARE A NEW INTELLECTUAL PROPERTY (AND NOT EXPLICITLY IN THE 2019 AGREEMENT), IMM CAN USE IT AT ITS ADVANTAGE TO RE-NEGOTIATE THE TERMS WITH AVION OR HAVE A SEPARATE AGREEMENT JUST FOR THE DIAGNOSTIC'S USE IN THE US.

WITHOUT DIAGNOSTICS WHICH IS A HIGHLY VALUABLE DISTINCT ASSET, ITS NOT WORTH HAVING LUPUS TRIALS. THE QUESTION ALSO BEGS CAN AVION REALLY AFFORD TO HAVE THE COSTS FOR THE DIAGNOSTICS. For argument sake, if IMM were to charge $1 Billion for the diagnostics to be used across all of the indications IN THE US, it does not appear that Avion can afford that, which brings me to my point I made some while ago and that is WE MAY SEE A BIG US PHARMA CO INVOLVEMENT THAT WOULD MAKE THE DEAL WITH AVION WORK

True potential about to be revealed

GLA

I like this RNS.

$10Billion Annually Diagnotis market, I do not believe Avion can afford. And, its Diagnostics that raises the bar for P140.

Immupharma could just go worldwide excluding the US if they wanted to so I believe the cards are firmly in IMM hands.

GLA

Gallmat

You have hit the nail with your final point, in case it came to that

And GLA

AND GLA

AND GLA

Medjed

Its part of this one:

RNS Number : 5871G

Mila Resources PLC

31 March 2022

Mila Resources Plc / Index: LSE / Epic: MILA / Sector: Natural Resources

31 March 2022

Mila Resources Plc

("Mila" or "the Company")

Interim Results

Mila Resources Plc, a London listed natural resources company, is pleased to present its interim results for the six-month period ended 31 December 2021.

GLA

HUGELY UNDERVALUED

GLA AND MERRY CHRISTMAS

"Testament to this commitment, within two weeks of acquiring our interest in Kathleen Valley we commenced a 11,000m drill campaign. The purpose of this drill campaign, which is still ongoing, is to build on the Project's initial JORC Inferred resource of 21,000 oz gold which, significantly, is part of a much larger JORC Exploration Target of 145,000-280,000 oz at 1.8-2.5g/t gold. It is important to note that this has been defined solely at the Coffey deposit ('Coffey'), in the southern area of the Project following just 12 reverse circulation drill holes totalling 2,160m. Accordingly, we are confident in our ability to enhance both the scale and confidence of the resource.

In December 2021 we received assay results for our first 11 drill holes, which exceeded our expectations. A stand-out result included the identification of a 10m wide zone of mineralisation with multiple +10g/t Au & Ag grades at Coffey, which our Chief Technical Officer, Neil Hutchison, described as "one of the most consistent and best overall gold intersections" he has seen in his 30-year career. This area is accordingly a high priority target and post period end has continued to deliver encouraging results, with a 9.3m wide mineralised sulphide zone from 195.7 to 205m identified that contains 2m of "Bellevue Style" quartz-sulphide lodes from 201.5m to 203.5m.

The discovery of "Bellevue Style" mineralisation is significant because underpinning our resource discovery confidence is Kathleen Valley's location. The Project is situated in one of the world's most productive gold regions, next to ASX listed Bellevue Gold Ltd ('Bellevue'), which has a market cap of circa AUD1 billion and is considered one of the most successful exploration plays in Western Australia. Evidence to date shows that Kathleen Valley exhibits similar geological characteristics to Bellevue, with gold-silver mineralisation occurring within the same Mt Goode Basalt sequence.

Encouragingly, mineralisation also appears to be improving with depth and now extends down dip for >150m, which is where we are currently focusing our drill efforts. Alongside Coffey, additional deposits will be tested in this current drill programme, including Sturrock and Powell in the north of the licence area where a zone of highly anomalous gold geochemistry has been identified.

We believe that the potential of this Project is substantial, and we are committed to unlocking it as swiftly as possible. Furthermore, the Project is in an area of established mining infrastructure being close to both the main Goldfields Highway and the electrical grid, and there are several gold processing plants in the district which may provide commercial development routes without the need to build a stand-alone processing plant, thus reducing future capital expenditure requirement.

Gold continues to appeal as a safe haven for investors, with a favourable pricing forecast ahead for the commodity"

WE ARE

Will have no choice but to sign up to a new deal alongside the old one, if they want access to the Diagnostic and therefore other indications. THAT IS IF THEY CAN AFFORD THE TERMS. I see a likely new major US pharma co involvement.

I also think that the old Agreement for Lupuzor will fall away once the Diagnostic side is built into a likely new Agreement in the US mentioned above.

GLA

Spot on Nettles

GLA

@roger65

A game changer at £2 ?- I would say more like £5 to £10 considering the annual cashflows size for both Diagnostic and Therapeutic that Tim talked about

GLA

I am convinced that, along with the massive drill results, we will likely also get a detailed roadmap to heights RP and EM are taking WSBN to. There is a good reason they want all the resukts in one go and its part of a bigger plan. Expect huge fireworks

GLA

In 6 years ggp is only going to spend 2m plus 2m. Thats a very very poor deal in my view. Compare this with when Newmont had entered into jv with OMI. Ggp knows they have the plant and dictate their terms. But, WSBN is planning something very different. I am convinced Ggp has been in touch with Wsbn but RP would have none of it. RP has b8g connections in Dubai whete he ran the gold trading from.

GLA

@Copperhands

I wonder id GGP had made behind the scenes a similar approach to WSBN but on their terms which RP did not like it as he has said before that big miners take away a large percentage of your asset (in this case say 75%) for a piddly sum. RP knows we have a monster so why not instead do a share consolidation, get the future funding ourselves, get the service companies in to do the digging, why not build the road towards Nifty and show two f.....s to GGP. RP and EM has this all planned I believe.

GLA

Particularly from 17.50 onwards, THE PLAN IS TO ATTRACT MAJORS

https://youtu.be/tKtTYQuO9bY?si=kANgu_hiGtHP3Lx_

*tier1